AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
AbbVie said its Phase 3 CERVINO trial showed investigational multiple-myeloma therapy etentamig delivered a 74% objective response rate and cut the risk of progression or death by 60% versus investigator-selected standard therapies. The result strengthens AbbVie’s oncology pipeline, but the commercial read still depends on regulatory review, durability data and the eventual treatment positioning.
AbbVie reported topline results from the Phase 3 CERVINO trial of etentamig in patients with relapsed or refractory multiple myeloma. The investigational asset produced a 74% objective response rate and significantly improved progression-free survival against investigator's choice of standard available therapies. The progression-free-survival hazard ratio was 0.40, corresponding to a 60% reduction in the risk of disease progression or death versus the control arm.
The trial addresses a heavily treated multiple-myeloma population, where treatment response and the durability of disease control are central measures of clinical value. The full follow-up, overall-survival data, safety details and detailed subgroup results remain pending, leaving the size and persistence of the benefit beyond the headline measures unresolved.
For AbbVie, etentamig would add to a portfolio whose reported revenue was $61.2B in fiscal 2025, up 8.6% year over year. The mechanism linking the trial to the company is pipeline optionality: a successful development and approval path could create another oncology revenue stream, while the current figures show only clinical-trial performance rather than booked sales. The company reported $2.36 in diluted EPS and a 6.9% net margin for the same fiscal period.
The evidence is positive but remains preliminary. The comparator was investigator's choice, so the specific therapies used in the control arm and their distribution matter when assessing how broadly the result translates across clinical practice. Regulatory authorities will assess the full benefit-risk profile, including safety and follow-up data.
Key disclosures ahead include the complete CERVINO dataset, the timing and content of any regulatory submission, and subsequent agency decisions. Investors will need to see whether the 74% response rate is sustained with longer follow-up and whether the progression-free-survival advantage remains consistent across relevant patient groups. Whether etentamig has begun contributing revenue or remains a development-stage asset will also emerge in future reports.
The CERVINO result moves the clinical-pipeline risk to the upside for ABBV, with regulatory validation and durability data now the key tests of etentamig’s value.
The result adds a quantified oncology catalyst to a business that generated $61.2B of revenue in FY2025, with a 74% response rate and a hazard ratio of 0.40 providing stronger evidence than an early-stage signal. The read is positive, but the absence of full safety, durability and regulatory timing data argues for a measured setup rather than a large immediate repricing.
The trade fails if the full CERVINO dataset weakens the topline efficacy signal, reveals limiting safety issues, or regulatory review does not support the expected treatment positioning.
CoverageSource: PR Newswire · Published here THU, SEP 3 · 9:15 AM ET · the only report in this recordHow this is decided →
Earlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
Price context does not establish that the story caused the move.
A 74% objective response rate and a 0.40 progression-free-survival hazard ratio could make etentamig a meaningful oncology growth asset for AbbVie if confirmed in the complete dataset and accepted by regulators.
The bear case is limited but real: topline results omit full safety, follow-up and control-arm detail, so the commercial value of etentamig is not yet established.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →